Progenics Pharmaceuticals (PGNX +2.4%) completes enrollment in a Phase 2 study of PSMA ADC in metastatic castrate resistant prostate cancer.
The enrolled patients are chemotherapy experienced.
The company is also enrolling chemotherapy naive patients in a second cohort.
Top-line data from the chemotherapy experienced cohort is expected in January. (PR)